Using a dose‐finding benchmark to quantify the loss incurred by dichotomization in Phase II dose‐ranging studies

DOI10.1002/BIMJ.201900332zbMath1464.62469OpenAlexW3027749606WikidataQ96306871 ScholiaQ96306871MaRDI QIDQ4998796

Xavier Paoletti, Pavel Mozgunov, Thomas Jaki

Publication date: 9 July 2021

Published in: Biometrical Journal (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1002/bimj.201900332

zbMATH Keywords

dichotomizationphase IIcontinuous endpointdose-ranging trialsnonparametric optimal benchmark

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Related Items (1)

Rejoinder: response-adaptive randomization in clinical trials

This page was built for publication: Using a dose‐finding benchmark to quantify the loss incurred by dichotomization in Phase II dose‐ranging studies